Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The CAG repeat expansion mutation that causes Huntington Disease (HD) was discovered more than 20 years ago, yet no treatment has yet been developed to stop the relentless course of the disease. Nonetheless, substantial progress has been made in understanding HD pathogenesis. We review insights that have been gleaned from HD genetics, metabolism, and pathology; HD mouse and cell models; the structure, function and post-translational modification of normal and mutant huntingtin (htt) protein; gene expression profiles in HD cells and tissue; the neurotoxicy of mutant htt RNA; and the expression of an antisense transcript from the HD locus. We conclude that rationale therapeutics for HD is within sight, though many questions remain to be answered.

Original languageEnglish (US)
Title of host publicationHandbook of Clinical Neurology
PublisherElsevier B.V.
Pages15-28
Number of pages14
Volume144
DOIs
StatePublished - Jan 1 2017

Publication series

NameHandbook of Clinical Neurology
Volume144
ISSN (Print)0072-9752
ISSN (Electronic)2212-4152

Fingerprint

Huntington Disease
Therapeutics
Antisense RNA
Mutant Proteins
Post Translational Protein Processing
Transcriptome
Pathology
Mutation

Keywords

  • aggregation
  • antisense
  • gene transcription
  • Huntingtin
  • inclusion

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Ross, C. A., Kronenbuerger, M., Duan, W., & Margolis, R. L. (2017). Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies. In Handbook of Clinical Neurology (Vol. 144, pp. 15-28). (Handbook of Clinical Neurology; Vol. 144). Elsevier B.V.. https://doi.org/10.1016/B978-0-12-801893-4.00002-X

Mechanisms underlying neurodegeneration in Huntington disease : applications to novel disease-modifying therapies. / Ross, Christopher A; Kronenbuerger, Martin; Duan, Wenzhen; Margolis, Russell Louis.

Handbook of Clinical Neurology. Vol. 144 Elsevier B.V., 2017. p. 15-28 (Handbook of Clinical Neurology; Vol. 144).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ross, CA, Kronenbuerger, M, Duan, W & Margolis, RL 2017, Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies. in Handbook of Clinical Neurology. vol. 144, Handbook of Clinical Neurology, vol. 144, Elsevier B.V., pp. 15-28. https://doi.org/10.1016/B978-0-12-801893-4.00002-X
Ross CA, Kronenbuerger M, Duan W, Margolis RL. Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies. In Handbook of Clinical Neurology. Vol. 144. Elsevier B.V. 2017. p. 15-28. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-12-801893-4.00002-X
Ross, Christopher A ; Kronenbuerger, Martin ; Duan, Wenzhen ; Margolis, Russell Louis. / Mechanisms underlying neurodegeneration in Huntington disease : applications to novel disease-modifying therapies. Handbook of Clinical Neurology. Vol. 144 Elsevier B.V., 2017. pp. 15-28 (Handbook of Clinical Neurology).
@inbook{bae16a8eb87644d3a73f92efa154b589,
title = "Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies",
abstract = "The CAG repeat expansion mutation that causes Huntington Disease (HD) was discovered more than 20 years ago, yet no treatment has yet been developed to stop the relentless course of the disease. Nonetheless, substantial progress has been made in understanding HD pathogenesis. We review insights that have been gleaned from HD genetics, metabolism, and pathology; HD mouse and cell models; the structure, function and post-translational modification of normal and mutant huntingtin (htt) protein; gene expression profiles in HD cells and tissue; the neurotoxicy of mutant htt RNA; and the expression of an antisense transcript from the HD locus. We conclude that rationale therapeutics for HD is within sight, though many questions remain to be answered.",
keywords = "aggregation, antisense, gene transcription, Huntingtin, inclusion",
author = "Ross, {Christopher A} and Martin Kronenbuerger and Wenzhen Duan and Margolis, {Russell Louis}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-801893-4.00002-X",
language = "English (US)",
volume = "144",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier B.V.",
pages = "15--28",
booktitle = "Handbook of Clinical Neurology",

}

TY - CHAP

T1 - Mechanisms underlying neurodegeneration in Huntington disease

T2 - applications to novel disease-modifying therapies

AU - Ross, Christopher A

AU - Kronenbuerger, Martin

AU - Duan, Wenzhen

AU - Margolis, Russell Louis

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The CAG repeat expansion mutation that causes Huntington Disease (HD) was discovered more than 20 years ago, yet no treatment has yet been developed to stop the relentless course of the disease. Nonetheless, substantial progress has been made in understanding HD pathogenesis. We review insights that have been gleaned from HD genetics, metabolism, and pathology; HD mouse and cell models; the structure, function and post-translational modification of normal and mutant huntingtin (htt) protein; gene expression profiles in HD cells and tissue; the neurotoxicy of mutant htt RNA; and the expression of an antisense transcript from the HD locus. We conclude that rationale therapeutics for HD is within sight, though many questions remain to be answered.

AB - The CAG repeat expansion mutation that causes Huntington Disease (HD) was discovered more than 20 years ago, yet no treatment has yet been developed to stop the relentless course of the disease. Nonetheless, substantial progress has been made in understanding HD pathogenesis. We review insights that have been gleaned from HD genetics, metabolism, and pathology; HD mouse and cell models; the structure, function and post-translational modification of normal and mutant huntingtin (htt) protein; gene expression profiles in HD cells and tissue; the neurotoxicy of mutant htt RNA; and the expression of an antisense transcript from the HD locus. We conclude that rationale therapeutics for HD is within sight, though many questions remain to be answered.

KW - aggregation

KW - antisense

KW - gene transcription

KW - Huntingtin

KW - inclusion

UR - http://www.scopus.com/inward/record.url?scp=85037033231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037033231&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801893-4.00002-X

DO - 10.1016/B978-0-12-801893-4.00002-X

M3 - Chapter

C2 - 28947113

AN - SCOPUS:85037033231

VL - 144

T3 - Handbook of Clinical Neurology

SP - 15

EP - 28

BT - Handbook of Clinical Neurology

PB - Elsevier B.V.

ER -